Archive for the ‘IDIBAPS’ Category

Tuesday January 10th, 2017

Transplant Biomedical receives an economical injection to develop an organ preservation device

Transplant Biomedical, one of the two spin-offs arising from IDIBAPS, will receive a maximum of 2.5 million euros to carry out the clinical phase of a medical device intended to improve the preservation and transport of kidneys and livers for transplantation. This economic injection is the result of an agreement with Caixa Capital Risc and Kereon Partners, the company founded, among others, by Carmen Peralta, coordinator of the group Strategies for the protection of hepatic injury induced by ischemia-reperfusion. Read the rest of this entry »

Comments Closed

Categories

Posted in:

Wednesday January 04th, 2017

A new drug has been developed for the treatment of autoimmune diseases

IDIBAPS researchers have participated in a study that shows how a new experimental drug could curb a wide variety of autoimmune diseases such as asthma, psoriasis, Crohn’s disease or multiple sclerosis without blocking the body’s natural response against infections caused by pathogens.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Friday December 23rd, 2016

IDIBAPS is the Spanish biomedical center that has received more funds from Horizon 2020 in 2015

The European Commission has published the Horizon 2020 Monitoring report for 2015. This document includes, among others, the 50 institutions that have received the most funding for research in the calls made up to 2015.

Read the rest of this entry »

Comments Closed
Thursday December 22nd, 2016

Blanca Molins receives the Julián García Sánchez award for research on vision issues

Blanca Molins rep el premi Julián García Sánchez de recerca en temes de la visió Read the rest of this entry »

Comments Closed
Thursday December 15th, 2016

New cellular reprogramming technique counters hallmarks of aging

Scientists from Salk Institute for Biological Studies showed that One clue to halting or reversing aging lies in the study of cellular reprogramming, a process in which the expression of four genes known as the Yamanaka factors allows scientists to convert any cell into induced pluripotent stem cells (iPSCs) Like embryonic stem calls, iPSCs are capable of dividing indefinitely and becoming any cell type present in our body. Dr. Juan Carlos Izpisúa Belmonte, professor in Salk’s Gene Expression Laboratory, is the senior author of the paper, published in Cell, in which also participated Dr. Josep Maria Campistol, CEO and nephrologist in Hospital Clínic, and researcher in IDIBAPS. Scientists from Universidad Católica de Murcia, among others, have also been involved. Read the rest of this entry »

Comments Closed

Categories

Posted in:

Marc Claret receives a ‘Consolidator Grant’ from the European Research Council

Marc Claret, head of the IDIBAPS Group Neuronal Control of Metabolism, has received a Consolidator Grant from the European Research Council (ERC) to study the populations of neurons that regulate the body’s energy status.

Read the rest of this entry »

Comments Closed
Page 5 of 75« First...34567...Last »